Table of Content

1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Overview
1.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Overview
1.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Segment by Type
1.2.1 TJM-F92 Strain
1.2.2 GDr180 Strain
1.2.3 JXA1-R Strain
1.2.4 Other
1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Type
1.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Overview by Type (2018-2029)
1.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size Review by Type (2018-2024)
1.3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Type (2018-2024)
1.4.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Type (2018-2024)
2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competition by Company
2.1 Global Top Players by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (2018-2024)
2.2 Global Top Players by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2024)
2.3 Global Top Players by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (2018-2024)
2.4 Global Top Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base Distribution, Sales Area, Product Type
2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competitive Situation and Trends
2.5.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2022)
2.7 Date of Key Manufacturers Enter into Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market
2.8 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Status and Outlook by Region
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Region
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Region (2018-2024)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Region (2018-2024)
3.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Region
3.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Region (2024-2029)
3.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Region (2024-2029)
3.3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Application
4.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Segment by Application
4.1.1 Farms
4.1.2 Individual
4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Overview by Application (2018-2029)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size Review by Application (2018-2024)
4.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Application (2018-2024)
4.3.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Breakdown by Application (2018-2024)
5 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
5.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Country
5.1.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2018-2024)
5.1.3 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2018-2024)
5.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Country
5.2.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2024-2029)
5.2.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2024-2029)
6 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
6.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Country
6.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2018-2024)
6.1.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2018-2024)
6.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Country
6.2.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2024-2029)
6.2.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2024-2029)
7 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Region
7.1 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Region
7.1.1 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Region
7.2.1 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Region (2024-2029)
8 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
8.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Country
8.1.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2018-2024)
8.1.3 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2018-2024)
8.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Country
8.2.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2024-2029)
8.2.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2024-2029)
9 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country
9.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historic Market Size by Country
9.1.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Market Size by Country
9.2.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Yongshun Creatures
10.1.1 Yongshun Creatures Company Information
10.1.2 Yongshun Creatures Introduction and Business Overview
10.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.1.5 Yongshun Creatures Recent Development
10.2 Keqian Biology
10.2.1 Keqian Biology Company Information
10.2.2 Keqian Biology Introduction and Business Overview
10.2.3 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.2.5 Keqian Biology Recent Development
10.3 Boehringer Ingelheim
10.3.1 Boehringer Ingelheim Company Information
10.3.2 Boehringer Ingelheim Introduction and Business Overview
10.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.3.5 Boehringer Ingelheim Recent Development
10.4 Sinovet
10.4.1 Sinovet Company Information
10.4.2 Sinovet Introduction and Business Overview
10.4.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.4.5 Sinovet Recent Development
10.5 Elanco
10.5.1 Elanco Company Information
10.5.2 Elanco Introduction and Business Overview
10.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.5.5 Elanco Recent Development
10.6 MSD
10.6.1 MSD Company Information
10.6.2 MSD Introduction and Business Overview
10.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.6.4 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.6.5 MSD Recent Development
10.7 Cahic
10.7.1 Cahic Company Information
10.7.2 Cahic Introduction and Business Overview
10.7.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.7.5 Cahic Recent Development
10.8 Ringpu
10.8.1 Ringpu Company Information
10.8.2 Ringpu Introduction and Business Overview
10.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.8.5 Ringpu Recent Development
10.9 Baoling
10.9.1 Baoling Company Information
10.9.2 Baoling Introduction and Business Overview
10.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.9.5 Baoling Recent Development
10.10 Jizhong
10.10.1 Jizhong Company Information
10.10.2 Jizhong Introduction and Business Overview
10.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.10.5 Jizhong Recent Development
10.11 Dahuanong
10.11.1 Dahuanong Company Information
10.11.2 Dahuanong Introduction and Business Overview
10.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.11.5 Dahuanong Recent Development
10.12 Hayao
10.12.1 Hayao Company Information
10.12.2 Hayao Introduction and Business Overview
10.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.12.5 Hayao Recent Development
10.13 Pulike Biology
10.13.1 Pulike Biology Company Information
10.13.2 Pulike Biology Introduction and Business Overview
10.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.13.5 Pulike Biology Recent Development
10.14 Tecon
10.14.1 Tecon Company Information
10.14.2 Tecon Introduction and Business Overview
10.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered
10.14.5 Tecon Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industrial Chain Analysis
11.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Dynamics
11.4.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Trends
11.4.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
11.4.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
11.4.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors
12.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of TJM-F92 Strain
Table 2. Major Company of GDr180 Strain
Table 3. Major Company of JXA1-R Strain
Table 4. Major Company of Other
Table 5. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US& Million)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share in Value by Type (2018-2024)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type (2018-2024) & (US$/Box)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type (2024-2029)
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type (2024-2029) & (US$/Box)
Table 16. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 17. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2018-2024)
Table 19. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2018-2024)
Table 21. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2018-2024)
Table 23. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2018-2024)
Table 25. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Company (2018-2024) & (Box)
Table 27. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Company (2018-2024)
Table 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Company (2018-2024)
Table 30. Global Market Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Company (2018-2024) & (US$/Box)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2022)
Table 34. Date of Key Manufacturers Enter into Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market
Table 35. Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 39. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Region (2018-2024)
Table 42. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 43. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 44. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Region (2024-2029)
Table 47. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2024-2029)
Table 48. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 50. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application (2018-2024)
Table 53. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application (2018-2024) & (US$/Box)
Table 54. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 55. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application (2024-2029)
Table 58. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application (2024-2029) & (US$/Box)
Table 59. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) (Box)
Table 60. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) (Box)
Table 62. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) (Box)
Table 64. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) (Box)
Table 66. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) (Box)
Table 68. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 70. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2018-2024)
Table 73. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 74. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 78. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 82. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 86. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 90. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 94. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 98. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 102. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 106. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Country (2024-2029)
Table 109. Yongshun Creatures Company Information
Table 110. Yongshun Creatures Introduction and Business Overview
Table 111. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 112. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 113. Yongshun Creatures Recent Development
Table 114. Keqian Biology Company Information
Table 115. Keqian Biology Introduction and Business Overview
Table 116. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 117. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 118. Keqian Biology Recent Development
Table 119. Boehringer Ingelheim Company Information
Table 120. Boehringer Ingelheim Introduction and Business Overview
Table 121. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 122. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 123. Boehringer Ingelheim Recent Development
Table 124. Sinovet Company Information
Table 125. Sinovet Introduction and Business Overview
Table 126. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 127. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 128. Sinovet Recent Development
Table 129. Elanco Company Information
Table 130. Elanco Introduction and Business Overview
Table 131. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 132. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 133. Elanco Recent Development
Table 134. MSD Company Information
Table 135. MSD Introduction and Business Overview
Table 136. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 137. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 138. MSD Recent Development
Table 139. Cahic Company Information
Table 140. Cahic Introduction and Business Overview
Table 141. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 142. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 143. Cahic Recent Development
Table 144. Ringpu Company Information
Table 145. Ringpu Introduction and Business Overview
Table 146. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 147. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 148. Ringpu Recent Development
Table 149. Baoling Company Information
Table 150. Baoling Introduction and Business Overview
Table 151. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 152. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 153. Baoling Recent Development
Table 154. Jizhong Company Information
Table 155. Jizhong Introduction and Business Overview
Table 156. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 157. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 158. Jizhong Recent Development
Table 159. Dahuanong Company Information
Table 160. Dahuanong Introduction and Business Overview
Table 161. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 162. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 163. Dahuanong Recent Development
Table 164. Hayao Company Information
Table 165. Hayao Introduction and Business Overview
Table 166. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 167. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 168. Hayao Recent Development
Table 169. Pulike Biology Company Information
Table 170. Pulike Biology Introduction and Business Overview
Table 171. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 172. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 173. Pulike Biology Recent Development
Table 174. Tecon Company Information
Table 175. Tecon Introduction and Business Overview
Table 176. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (Million USD), Price (US$/Box) and Gross Margin (2018-2024)
Table 177. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 178. Tecon Recent Development
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends
Table 182. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
Table 183. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
Table 184. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
Table 185. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 186. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Downstream Customers
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Picture
Figure 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Status and Outlook (2018-2029) & (Box)
Figure 5. Product Picture of TJM-F92 Strain
Figure 6. Global TJM-F92 Strain Sales YoY Growth (2018-2029) & (Box)
Figure 7. Product Picture of GDr180 Strain
Figure 8. Global GDr180 Strain Sales YoY Growth (2018-2029) & (Box)
Figure 9. Product Picture of JXA1-R Strain
Figure 10. Global JXA1-R Strain Sales YoY Growth (2018-2029) & (Box)
Figure 11. Product Picture of Other
Figure 12. Global Other Sales YoY Growth (2018-2029) & (Box)
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type in 2022 & 2029
Figure 15. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type in 2022
Figure 16. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type in 2022
Figure 17. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type in 2022
Figure 18. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type in 2022
Figure 21. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue in 2022
Figure 27. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Farms
Figure 29. Global Farms Sales YoY Growth (2018-2029) & (Box)
Figure 30. Product Picture of Individual
Figure 31. Global Individual Sales YoY Growth (2018-2029) & (Box)
Figure 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029) & (US$ Million)
Figure 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application in 2022 & 2029
Figure 34. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application in 2022
Figure 35. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application in 2022
Figure 36. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application in 2022
Figure 37. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application in 2022
Figure 40. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Cost Structure
Figure 45. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed